US FDA halts CTI BioPharma's Ph III cancer drug trial after patient deaths

By Gareth Macdonald

- Last updated on GMT

CTI BioPharma HQ in Seattle, US
CTI BioPharma HQ in Seattle, US

Related tags Clinical trial

The US FDA has ordered CTI BioPharma to halt a Phase III trial of a cancer drug candidate after patients died from “intracranial hemorrhage, cardiac failure and cardiac arrest.”

The Seattle, US based biotech announced the halt this week, explaining that it received an oral communication from the FDA followed by a letter confirming the IND for pacritinib has been placed on full clinical hold.

CTI BioPharma also said it has withdrawn its New Drug Application (NDA) for the drug until it "has had a chance to review the safety and efficacy data​." 

The firm added that: "Under the full clinical hold, all patients currently on pacritinib must discontinue pacritinib immediately and no patients can be enrolled or start pacritinib as initial or crossover treatment.

"All clinical investigators worldwide have been delivered a notice of the full clinical hold."

According to CTI​ the FDA imposed a partial hold on the study on February 4 in response to "excess mortality and other adverse events in pacritinib-treated patients​."

Global trial 

The Phase III study - known as PERSIST-2​ - is examining whether "once-daily or twice-daily pacritinib results in a greater proportion of patients with thrombocytopenia and myelofibrosis achieving ≥ 35% reduction in spleen volume from baseline​."

The drug is being tested at sites in the US, Australia, Belgium, Canada, the Czech Republic, France, Germany, Hungary, The Netherlands, New Zealand, Russia and the UK. It has enrolled an estimated 300 people according to the latest information on US trial registry,

CTI BioPharma is planning to commercialize pacritinib with Baxalta - previously known as Baxter International - which licensed rights to the drug in 2013 for $60m upfront and an agreement to pay milestones of up to $112m.


At present the Seattle biotech's only approved product is a drug called Pixuvri (pixantrone) that was cleared to treat aggressive B-cell non-Hodgkin lymphoma (NHL) by European authorities 2012​. 

French drugmaker Servier licensed commercialisation rights to pixantrone in September 2014 for an upfront payment of $18.1m (€14m).

Under the deal Servier has the right to commercialize the drug in all countries except Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the UK and the US. In addition to the upfront payment, the France drugmaker also pays royalties on sales.

Related news

Show more

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more